BioSpace News Archive

Sight Sciences, Inc. an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced the 1,000th installation of its TearCare® System.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6.

Mitsubishi Tanabe Pharma America, Inc. announced that nearly 4,000 people with amyotrophic lateral sclerosis have received RADICAVA ORS® since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous RADICAVA® between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.

XyloCor Therapeutics today announced completion of the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.

Centessa Pharmaceuticals plc today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors.

Dynatronics Corporation today announced that the company will release financial results for its second quarter of fiscal year 2023 on Thursday, February 9, 2023 before the market opens.

Veru Inc. today announced it will host a conference call and audio webcast on Thursday, February 9, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 first quarter financial results and provide a business update.

Bone Biologics Corporation announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1.

Devonian Health Group Inc. is pleased to announce that Mr. Pierre Montanaro, President and Chief Executive Officer of the Corporation, is scheduled to present at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023.

Elaborate, the tool that doctors and their staff use to deliver contextualized, action-oriented lab results to patients, announced today it has raised $10 million in Seed funding.